Methamphetamine-associated psychosis (MAP) has been considered a pharmacological or environmental pathogen model of schizophrenia (SCZ) due in part to similarities in clinical presentation (i.e. paranoia, hallucinations, disorganized speech, and negative symptoms), response to treatment (e.g.neuroleptics),and pathologic mechanisms (e.g. central dopaminergic neurotransmission) of both conditions. Both risperidone and aripiprazole are second generation antipsychotics，but have different pharmacological effects of antipsychotic treatment.This study was designed to examine the acute efficacy, safety, and tolerability of risperidone and aripiprazole for patients with MAP.
Methods:A Multiple-Center, Randomized, Double-Blind.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
50
Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
Aripiprazole group,5mg/pill,20mg-30mg/day non-forced titration method,last 2-4weeks
The Second Xiangya Hospital of Central University
Changsha, Hunan, China
The severity of psychosis
Positive and Negative Syndrome Scale
Time frame: up to 4 weeks. participants will be followed for the duration of hospital stay
adverse drug reaction
Barnes Scale , Simpson-Angus Scale , Abnormal Involuntary Movement Scale
Time frame: up to 4 weeks. participants will be followed for the duration of hospital
Clinical general status
Clinical general rating scale
Time frame: up to 4 weeks. participants will be followed for the duration of hospital stay
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.